The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jul. 19, 2016

Filed:

Apr. 14, 2014
Applicant:

The United States of America, As Represented BY the Secretary, Department of Health and Human Services, Washington, DC (US);

Inventors:

Xin Wei Wang, Rockville, MD (US);

Stephanie K. Roessler, Heidelberg, DE;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 48/00 (2006.01); C07K 16/18 (2006.01); G01N 33/574 (2006.01); C12N 15/113 (2010.01); C12N 15/85 (2006.01); C12N 15/86 (2006.01); C12Q 1/68 (2006.01);
U.S. Cl.
CPC ...
C07K 16/18 (2013.01); C12N 15/113 (2013.01); C12N 15/85 (2013.01); C12N 15/86 (2013.01); C12Q 1/6886 (2013.01); G01N 33/57415 (2013.01); G01N 33/57438 (2013.01); C12Q 1/6841 (2013.01); C12Q 2600/112 (2013.01); C12Q 2600/118 (2013.01); C12Q 2600/136 (2013.01); C12Q 2600/158 (2013.01); G01N 2800/50 (2013.01);
Abstract

Disclosed herein is a driver gene signature for predicting survival in patients with solid tumors, such as hepatocellular carcinoma (HCC) and breast cancer. The gene signature includes ten tumor-associated genes, SH2D4A, CCDC25, ELP3, DLC1, PROSC, SORBS3, HNRPD, PAQR3, PHF17 and DCK. A decrease in DNA copy number or mRNA expression of SH2D4A, CCDC25, ELP3, DLC1, PROSC and SORBS3 in solid tumors is associated with a poor prognosis, while a decrease in DNA copy number or mRNA expression of HNRPD, PAQR3, PHF17 and DCK in solid tumors is associated with a good prognosis. Methods of predicting the prognosis of a patient diagnosed with HCC or breast cancer by detecting expression of one of more tumor-associated genes, and methods of treating a patient diagnosed with HCC or breast cancer by administering an agent that alters expression or activity of one or more of the disclosed tumor-associated genes, are described.


Find Patent Forward Citations

Loading…